Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience

The Prostate ◽  
2021 ◽  
Author(s):  
Christopher E. Wee ◽  
Brian A. Costello ◽  
Jacob J. Orme ◽  
J. Fernando Quevedo ◽  
Lance C. Pagliaro
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Small Cell ◽  
Single Institution ◽  
Carcinoma Of The Prostate

scholarly journals Review of Small Cell Carcinomas of the Prostate

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
P. Furtado ◽  
M. V. A. Lima ◽  
C. Nogueira ◽  
M. Franco ◽  
F. Tavora
Keyword(s):  
Radiation Therapy ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Neuroendocrine Carcinoma ◽  
Advanced Disease ◽  
Small Cell ◽  
High Grade ◽  
Small Cell Neuroendocrine Carcinoma ◽  
Rare Neoplasm ◽  
Carcinoma Of The Prostate

Small cell carcinoma of the prostate is a rare neoplasm, with only a few series hitherto reported. A little less than half of the cases are associated with conventional acinar adenocarcinoma, which are usually high grade. Although consensus has not been reached, the majority of patients with small cell neuroendocrine carcinoma of the prostate have advanced disease at diagnosis and disproportionally low PSA levels compared to patients with conventional acinar adenocarcinoma. Treatment consists mainly of chemotherapy associated with surgery. Radiation therapy is reserved for selected cases. This study reviews the most up-to-date information on small cell carcinomas of the prostate.

scholarly journals Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Phoenix D. Bell ◽  
Aaron R. Huber ◽  
Diana Agostini-Vulaj
Keyword(s):  
Neuroendocrine Carcinoma ◽  
Specific Antigen ◽  
Case Series ◽  
Small Cell ◽  
Ki 67 ◽  
Carcinoma Of The Prostate ◽  
Dismal Prognosis ◽  
Case Presentations ◽  
Aggressive Subtype ◽  
Median Interval

Abstract Background Small cell neuroendocrine carcinoma of the prostate (SCNECP) is a rare, aggressive subtype of prostate carcinoma. Most SCNECP arise from conventional prostate adenocarcinoma (CPAC) treated with androgen deprivation therapy (ADT). Case presentations We identified four cases of CPAC treated with ADT, which evolved to SCNECP with liver metastasis. The average interval between the diagnosis of CPAC and SCNECP was 102 months (range: 12 to 168). Histologically, the tumors showed nests of cells with high nuclear:cytoplasmic ratios, granular chromatin, and frequent mitoses. All cases were synaptophysin, chromogranin, and AE1/AE3 positive, with a Ki-67 labeling index ≥70%. NKX3.1 was negative in all but one case and TTF-1 was positive in half. Weak ERG positivity by IHC was seen in one case which also demonstrated the TMPRSS2-ERG gene rearrangement; all other cases were negative for ERG by IHC. Serum prostate specific antigen (PSA) levels were normal to near-normal in all. The median interval between the diagnosis of SCNECP and death was 3.25 months (range: 0.75 to 26). Conclusions Our case series highlights the importance of considering a prostate primary, even in the setting of normal PSA levels and loss of prostate markers, when diagnosing neuroendocrine carcinoma in the liver. Further, we emphasize the significance of diagnosing SCNECP that metastasizes to the liver, as it portends a particularly dismal prognosis.

Sign in / Sign up

Export Citation Format

Share Document